menthol has been researched along with Ache in 43 studies
Menthol: A monoterpene cyclohexanol produced from mint oils.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We determined the effects of topically applied (i) isolated menthol cream, (ii) menthol and capsaicin co-application or (iii) placebo cream on exercise tolerance, thermal perception, pain, attentional focus and thermoregulation during exercise in the heat." | 9.69 | Topical application of isolated menthol and combined menthol-capsaicin creams: Exercise tolerance, thermal perception, pain, attentional focus and thermoregulation in the heat. ( Heffernan, SM; Jeffries, O; John, K; Page, J; Peel, J; Tallent, J; Waldron, M, 2023) |
| "Both health professionals and consumers use menthol-based topical analgesics extensively for the temporary relief of pain from musculoskeletal ailments or injury." | 9.51 | Menthol-Based Topical Analgesic Induces Similar Upper and Lower Body Pain Pressure Threshold Values: A Randomized Trial. ( Alizadeh, S; Behm, DG; Brosky, JA; Herat, N; Page, P; Power, GMJ, 2022) |
| "Burdens related to pain, smoking/nicotine dependence, and pain-smoking comorbidity disproportionately impact Black Americans, and menthol cigarette use is overrepresented among Black adults who smoke cigarettes." | 8.31 | Pain and Menthol Use Are Related to Greater Nicotine Dependence Among Black Adults Who Smoke Cigarettes at Wave 5 (2018-2019) of the Population Assessment of Tobacco and Health (PATH) Study. ( Deyo, AG; Ditre, JW; Heckman, BW; Powers, JM; Rubenstein, D; Terry, EL; Zale, EL, 2023) |
| "Nicotine has acute pain-relieving properties, and tobacco smokers often report using cigarettes to cope with pain." | 7.91 | Menthol cigarette use and pain reporting among African American adults seeking treatment for smoking cessation. ( Buckner, JD; Ditre, JW; Hughes, MT; Kosiba, JD; LaRowe, LR; Norton, PJ; Smits, JAJ; Zvolensky, MJ, 2019) |
| " It is therefore hypothesized in this paper that the esophageal infusion of the TRPM8 activator menthol evokes cold sensations from the esophagus and alleviates heartburn in humans." | 7.91 | The infusion of menthol into the esophagus evokes cold sensations in healthy subjects but induces heartburn in patients with gastroesophageal reflux disease (GERD). ( Banovcin, P; Duricek, M; Hyrdel, R; Kollarik, M; Liptak, P; Zatko, T, 2019) |
| "Topical high-concentration L-menthol is the only established human experimental pain model to study mechanisms underlying cold hyperalgesia." | 7.81 | Cold and L-menthol-induced sensitization in healthy volunteers--a cold hypersensitivity analogue to the heat/capsaicin model. ( Andersen, HH; Arendt-Nielsen, L; Gazerani, P; Nikbakht, A; Poulsen, JN; Uchida, Y, 2015) |
| "Topical capsaicin is reported to be an effective treatment for idiopathic intractable pruritus ani." | 7.72 | Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key. ( Anand, P, 2003) |
| "The effect of menthol and alcohol as its vehicle on thermal sensations, pain, experimental itch and irritation were studied in 18 subjects, using a computerized thermal sensory analyzer, laser Doppler flowmetry and an evaporimeter for transepidermal water loss (TEWL)." | 7.69 | Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. ( Hui, XY; Maibach, H; Szolar, C; Yosipovitch, G, 1996) |
| "We determined the effects of topically applied (i) isolated menthol cream, (ii) menthol and capsaicin co-application or (iii) placebo cream on exercise tolerance, thermal perception, pain, attentional focus and thermoregulation during exercise in the heat." | 5.69 | Topical application of isolated menthol and combined menthol-capsaicin creams: Exercise tolerance, thermal perception, pain, attentional focus and thermoregulation in the heat. ( Heffernan, SM; Jeffries, O; John, K; Page, J; Peel, J; Tallent, J; Waldron, M, 2023) |
| "Both health professionals and consumers use menthol-based topical analgesics extensively for the temporary relief of pain from musculoskeletal ailments or injury." | 5.51 | Menthol-Based Topical Analgesic Induces Similar Upper and Lower Body Pain Pressure Threshold Values: A Randomized Trial. ( Alizadeh, S; Behm, DG; Brosky, JA; Herat, N; Page, P; Power, GMJ, 2022) |
| "Menthol inhibited phototoxicity-evoked APs and reduced pain behavior when applied topically to mice." | 5.48 | Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy. ( Baptista-Hon, D; Bull, F; Dalgaty, F; Gallacher, M; Hales, TG; Ibbotson, SH; Wright, L, 2018) |
| " The search terms used were 'TRP channel AND plant compound', 'cough AND plant compound', 'cough AND TRP channels AND plant compound', 'cough AND P2X3 AND plant compound' and 'P2X3 AND plant compound' where plant compound represents menthol or camphor or eucalyptus or turpentine or thymol." | 5.41 | Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies. ( Morice, AH; Sadofsky, LR; Stinson, RJ, 2023) |
| "Menthol is a natural compound of plant origin known to produce cool sensation via the activation of the TRPM8 channel." | 5.38 | Menthol pain relief through cumulative inactivation of voltage-gated sodium channels. ( Delmas, P; Gabriac, M; Gaudioso, C; Hao, J; Martin-Eauclaire, MF, 2012) |
| "Cold hyperalgesia is 1 of the characteristic signs in neuropathic pain." | 5.37 | Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. ( Baron, R; Binder, A; Klebe, O; Stengel, M; Wasner, G, 2011) |
| "Menthol has been used as a non-opioid pain reliever since ancient times." | 4.98 | The role and mechanism of action of menthol in topical analgesic products. ( LeQuang, JA; Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Burdens related to pain, smoking/nicotine dependence, and pain-smoking comorbidity disproportionately impact Black Americans, and menthol cigarette use is overrepresented among Black adults who smoke cigarettes." | 4.31 | Pain and Menthol Use Are Related to Greater Nicotine Dependence Among Black Adults Who Smoke Cigarettes at Wave 5 (2018-2019) of the Population Assessment of Tobacco and Health (PATH) Study. ( Deyo, AG; Ditre, JW; Heckman, BW; Powers, JM; Rubenstein, D; Terry, EL; Zale, EL, 2023) |
| "and purpose: Phenazopyridine (PAP) is an over-the-counter drug widely used to provide symptomatic relief of bladder pain in conditions such as cystitis or bladder pain syndrome (BPS)." | 4.31 | Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine. ( Bazeli, B; Daniluk, J; Everaerts, W; Freitas, ACN; Janssens, A; Luyts, N; Mulier, M; Voets, T, 2023) |
| "Nicotine has acute pain-relieving properties, and tobacco smokers often report using cigarettes to cope with pain." | 3.91 | Menthol cigarette use and pain reporting among African American adults seeking treatment for smoking cessation. ( Buckner, JD; Ditre, JW; Hughes, MT; Kosiba, JD; LaRowe, LR; Norton, PJ; Smits, JAJ; Zvolensky, MJ, 2019) |
| " It is therefore hypothesized in this paper that the esophageal infusion of the TRPM8 activator menthol evokes cold sensations from the esophagus and alleviates heartburn in humans." | 3.91 | The infusion of menthol into the esophagus evokes cold sensations in healthy subjects but induces heartburn in patients with gastroesophageal reflux disease (GERD). ( Banovcin, P; Duricek, M; Hyrdel, R; Kollarik, M; Liptak, P; Zatko, T, 2019) |
| "Topical high-concentration L-menthol is the only established human experimental pain model to study mechanisms underlying cold hyperalgesia." | 3.81 | Cold and L-menthol-induced sensitization in healthy volunteers--a cold hypersensitivity analogue to the heat/capsaicin model. ( Andersen, HH; Arendt-Nielsen, L; Gazerani, P; Nikbakht, A; Poulsen, JN; Uchida, Y, 2015) |
| "Topical capsaicin is reported to be an effective treatment for idiopathic intractable pruritus ani." | 3.72 | Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key. ( Anand, P, 2003) |
| "The effect of menthol and alcohol as its vehicle on thermal sensations, pain, experimental itch and irritation were studied in 18 subjects, using a computerized thermal sensory analyzer, laser Doppler flowmetry and an evaporimeter for transepidermal water loss (TEWL)." | 3.69 | Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. ( Hui, XY; Maibach, H; Szolar, C; Yosipovitch, G, 1996) |
| " Study I: A dose-response relationship (N = 20) between 0, 2, and 4 mg nicotine gum." | 2.82 | Psychophysical and Vasomotor Responses of the Oral Tissues: A Nicotine Dose-Response and Menthol Interaction Study. ( Arendt Nielsen, T; Arendt-Nielsen, L; Boudreau, SA; Nielsen, BP; Wang, K, 2016) |
| "Morphine was administered intramuscularly immediately prior to algogen administration." | 1.51 | Nociceptive-like behavior and analgesia in silver catfish (Rhamdia quelen). ( Baldisserotto, B; Barbosa, LB; Bianchini, AE; Ferrari, FT; Heinzmann, BM; Rodrigues, P, 2019) |
| "Menthol inhibited phototoxicity-evoked APs and reduced pain behavior when applied topically to mice." | 1.48 | Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy. ( Baptista-Hon, D; Bull, F; Dalgaty, F; Gallacher, M; Hales, TG; Ibbotson, SH; Wright, L, 2018) |
| " AMG2850 is potent in vitro at rat TRPM8 (IC90 against icilin activation of 204 ± 28 nM), highly selective (>100-fold IC90 over TRPV1 and TRPA1 channels), and orally bioavailable (F po > 40 %)." | 1.42 | AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia. ( Davis, C; Gavva, NR; Kerstein, PC; Lehto, SG; Stucky, CL; Wang, J; Wang, W; Weyer, AD; Wild, KD; Youngblood, BD; Zhang, M, 2015) |
| "Menthol is a natural compound of plant origin known to produce cool sensation via the activation of the TRPM8 channel." | 1.38 | Menthol pain relief through cumulative inactivation of voltage-gated sodium channels. ( Delmas, P; Gabriac, M; Gaudioso, C; Hao, J; Martin-Eauclaire, MF, 2012) |
| "Cold hyperalgesia is 1 of the characteristic signs in neuropathic pain." | 1.37 | Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. ( Baron, R; Binder, A; Klebe, O; Stengel, M; Wasner, G, 2011) |
| "Central neuropathic pain following lesions within the CNS, such as spinal cord injury, is one of the most excruciating types of chronic pain and one of the most difficult to treat." | 1.35 | Residual spinothalamic tract pathways predict development of central pain after spinal cord injury. ( Engel, S; Lee, BB; McLachlan, E; Wasner, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.30) | 18.7374 |
| 1990's | 1 (2.33) | 18.2507 |
| 2000's | 11 (25.58) | 29.6817 |
| 2010's | 20 (46.51) | 24.3611 |
| 2020's | 7 (16.28) | 2.80 |
| Authors | Studies |
|---|---|
| Baraldi, PG | 1 |
| Preti, D | 1 |
| Materazzi, S | 1 |
| Geppetti, P | 1 |
| Behm, DG | 1 |
| Herat, N | 1 |
| Power, GMJ | 1 |
| Brosky, JA | 1 |
| Page, P | 1 |
| Alizadeh, S | 1 |
| Powers, JM | 1 |
| Zale, EL | 1 |
| Deyo, AG | 1 |
| Rubenstein, D | 1 |
| Terry, EL | 1 |
| Heckman, BW | 1 |
| Ditre, JW | 2 |
| Luyts, N | 1 |
| Daniluk, J | 1 |
| Freitas, ACN | 1 |
| Bazeli, B | 1 |
| Janssens, A | 1 |
| Mulier, M | 1 |
| Everaerts, W | 1 |
| Voets, T | 1 |
| Stinson, RJ | 1 |
| Morice, AH | 1 |
| Sadofsky, LR | 1 |
| Peel, J | 1 |
| John, K | 1 |
| Page, J | 1 |
| Jeffries, O | 1 |
| Heffernan, SM | 1 |
| Tallent, J | 1 |
| Waldron, M | 1 |
| Halonen, L | 1 |
| Pemmari, A | 1 |
| Nummenmaa, E | 1 |
| Hämäläinen, M | 1 |
| Moilanen, T | 1 |
| Vuolteenaho, K | 1 |
| Moilanen, E | 1 |
| Rodrigues, P | 1 |
| Barbosa, LB | 1 |
| Bianchini, AE | 1 |
| Ferrari, FT | 1 |
| Baldisserotto, B | 1 |
| Heinzmann, BM | 1 |
| Esancy, K | 1 |
| Dhaka, A | 1 |
| Lai, PM | 1 |
| Collaku, A | 1 |
| Reed, K | 1 |
| Wright, L | 1 |
| Baptista-Hon, D | 1 |
| Bull, F | 1 |
| Dalgaty, F | 1 |
| Gallacher, M | 1 |
| Ibbotson, SH | 1 |
| Hales, TG | 1 |
| Li, K | 1 |
| Gao, S | 1 |
| Tian, B | 1 |
| Shi, Y | 1 |
| Lv, Q | 1 |
| Han, J | 1 |
| Pergolizzi, JV | 1 |
| Taylor, R | 1 |
| LeQuang, JA | 1 |
| Raffa, RB | 1 |
| Kosiba, JD | 1 |
| Hughes, MT | 1 |
| LaRowe, LR | 1 |
| Zvolensky, MJ | 1 |
| Norton, PJ | 1 |
| Smits, JAJ | 1 |
| Buckner, JD | 1 |
| Hondebrink, L | 1 |
| Opstelten, W | 1 |
| Banovcin, P | 1 |
| Duricek, M | 1 |
| Zatko, T | 1 |
| Liptak, P | 1 |
| Hyrdel, R | 1 |
| Kollarik, M | 1 |
| Wade, AG | 1 |
| Crawford, GM | 1 |
| Young, D | 1 |
| Corson, S | 1 |
| Brown, C | 1 |
| Lehto, SG | 1 |
| Weyer, AD | 1 |
| Zhang, M | 1 |
| Youngblood, BD | 1 |
| Wang, J | 1 |
| Wang, W | 1 |
| Kerstein, PC | 1 |
| Davis, C | 1 |
| Wild, KD | 1 |
| Stucky, CL | 1 |
| Gavva, NR | 1 |
| Andersen, HH | 1 |
| Poulsen, JN | 1 |
| Uchida, Y | 1 |
| Nikbakht, A | 1 |
| Arendt-Nielsen, L | 2 |
| Gazerani, P | 1 |
| Arendt Nielsen, T | 1 |
| Nielsen, BP | 1 |
| Wang, K | 1 |
| Boudreau, SA | 1 |
| Wasner, G | 3 |
| Lee, BB | 1 |
| Engel, S | 1 |
| McLachlan, E | 1 |
| Colvin, LA | 1 |
| Johnson, PR | 1 |
| Mitchell, R | 1 |
| Fleetwood-Walker, SM | 1 |
| Fallon, M | 1 |
| Caspani, O | 1 |
| Zurborg, S | 1 |
| Labuz, D | 1 |
| Heppenstall, PA | 1 |
| Liu, K | 1 |
| Samuel, M | 1 |
| Ho, M | 1 |
| Harrison, RK | 1 |
| Paslay, JW | 1 |
| Klein, AH | 1 |
| Sawyer, CM | 1 |
| Carstens, MI | 1 |
| Tsagareli, MG | 1 |
| Tsiklauri, N | 1 |
| Carstens, E | 1 |
| Binder, A | 2 |
| Stengel, M | 1 |
| Klebe, O | 1 |
| Baron, R | 2 |
| Roberts, K | 1 |
| Shenoy, R | 1 |
| Anand, P | 2 |
| Gaudioso, C | 1 |
| Hao, J | 1 |
| Martin-Eauclaire, MF | 1 |
| Gabriac, M | 1 |
| Delmas, P | 1 |
| Renner, B | 1 |
| Schreiber, K | 1 |
| Averbeck, B | 1 |
| Rucker, F | 1 |
| Laubender, RP | 1 |
| Carr, RW | 1 |
| KLEINMAN, H | 1 |
| COONEY, MK | 1 |
| NELSON, CB | 1 |
| OWEN, RR | 1 |
| BOYD, L | 1 |
| SWANDA, G | 1 |
| Schattschneider, J | 1 |
| Kraemer, WJ | 1 |
| Ratamess, NA | 1 |
| Maresh, CM | 1 |
| Anderson, JA | 1 |
| Volek, JS | 1 |
| Tiberio, DP | 1 |
| Joyce, ME | 1 |
| Messinger, BN | 1 |
| French, DN | 1 |
| Sharman, MJ | 1 |
| Rubin, MR | 1 |
| Gómez, AL | 1 |
| Silvestre, R | 1 |
| Hesslink, RL | 1 |
| Namer, B | 2 |
| Seifert, F | 1 |
| Handwerker, HO | 1 |
| Maihöfner, C | 1 |
| Liu, Y | 1 |
| Ye, X | 1 |
| Feng, X | 1 |
| Zhou, G | 1 |
| Rong, Z | 1 |
| Fang, C | 1 |
| Chen, H | 1 |
| Linte, RM | 1 |
| Ciobanu, C | 1 |
| Reid, G | 1 |
| Babes, A | 1 |
| Kleggetveit, IP | 1 |
| Handwerker, H | 1 |
| Schmelz, M | 1 |
| Jorum, E | 1 |
| Yosipovitch, G | 1 |
| Szolar, C | 1 |
| Hui, XY | 1 |
| Maibach, H | 1 |
| Acosta, MC | 1 |
| Belmonte, C | 1 |
| Gallar, J | 1 |
| Kobal, G | 1 |
| Raab, W | 1 |
| Lotz, H | 1 |
| White, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain[NCT02100670] | Phase 3 | 385 participants (Actual) | Interventional | 2013-11-01 | Completed | ||
| Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia[NCT05816226] | Phase 3 | 90 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | ||
| High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde[NCT02653703] | 14 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours
| Intervention | NRS Score (0 - 10 scale) * hrs (Mean) |
|---|---|
| 1% Diclofenac Sodium Plus (+) 3% Menthol | 276.97 |
| Placebo | 282.88 |
AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours
| Intervention | NRS Score (0 - 10 scale) * hrs (Mean) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 276.97 |
| 1% Diclofenac Sodium | 261.11 |
| 3% Menthol | 272.65 |
| Placebo | 282.88 |
"Time of onset of cooling sensation measured by time when subjects reported to have a 'cooling effect as an enhancement of pain relief'. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose Do you feel a cooling sensation at the injured ankle from the study gel?" (NCT02100670)
Timeframe: up to 6 hours
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 0.17 |
| 1% Diclofenac Sodium | 0.17 |
| 3% Menthol | 0.17 |
| Placebo | 0.17 |
"TOMR was measured by time when participants reported PRS ≥ 2, i.e. some or meaningful pain relief" (NCT02100670)
Timeframe: up to 10 days (end of study)
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 92.50 |
| 1% Diclofenac Sodium | 76.83 |
| 3% Menthol | 72.00 |
| Placebo | 93.50 |
"TOPR was measured by time when participants reported PRS ≥ 1, i.e. a little or perceptible pain relief'." (NCT02100670)
Timeframe: Baseline to 10 days (end of study)
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 1.03 |
| 1% Diclofenac Sodium | 4.00 |
| 3% Menthol | 1.00 |
| Placebo | 4.00 |
Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam). (NCT02100670)
Timeframe: up to 240 hours
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 240.00 |
| 1% Diclofenac Sodium | 240.00 |
| 3% Menthol | 240.00 |
| Placebo | 240.00 |
"Ankle swelling measured by figure of eight method of injured ankle." (NCT02100670)
Timeframe: Day 1 (baseline), 3, and 7
| Intervention | Millimeters (Mean) | ||
|---|---|---|---|
| At Day 1 | At Day 3 | At Day 7 | |
| 1% Diclofenac Sodium | 573.6 | 566.9 | 558.8 |
| 1% Diclofenac Sodium+3% Menthol | 573.9 | 566.2 | 558.3 |
| 3% Menthol | 577.1 | 567.0 | 558.4 |
| Placebo | 576.1 | 565.4 | 557.0 |
"PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.~Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days
| Intervention | score on scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PI at Baseline (n=117, 112, 77, 75) | PID at 10 min. (n=117, 112, 77, 75) | PID at 30 min. (n=117, 112, 77, 75) | PID at 1 hour (n=117, 112, 77, 75) | PID at 4 hour (n=117, 112, 77, 75) | PID at 6 hour (n=117, 112, 77, 75) | PID at 12 hour (n= 117, 112, 77, 75) | PID at 18 hour (n=117, 112, 77, 75) | PID at 24 hour (n=117, 112, 77, 75) | PID at 36 hour (n=117, 112, 77, 75) | PID at 48 hour (n=117, 112, 77, 75) | PID at 60 hour (n=117, 112, 77, 75) | PID at 72 hour (n=117, 112, 77, 75) | PID at 84 hour (n=113, 107, 75, 75) | PID at 96 hour (n=112, 107, 75, 74) | PID at 108 hour (n=112, 107, 75, 74) | PID at 120 hour (n=111, 107, 74, 74) | PID at 132 hour (n=110, 107, 74, 74) | PID at 144 hour (n=110, 107, 74, 74) | PID at 156 hour (n=109, 107, 74, 74) | PID at 168 hour (n=105, 104, 73, 74) | PID at 180 hour (n=105, 104, 73, 72) | PID at 192 hour (n=101, 102, 71, 72) | PID at 204 hour (n=101, 100, 71, 72) | PID at 216 hour (n=95, 100, 69, 72) | PID at 228 hour (n=95, 100, 69, 72) | PID at 240 hour (n=32, 43, 22, 42) | |
| 1% Diclofenac Sodium | 7.4 | 0.19 | 0.36 | 0.50 | 0.48 | 0.67 | 0.99 | 1.32 | 1.58 | 1.65 | 2.01 | 2.26 | 2.42 | 2.68 | 2.78 | 3.01 | 3.17 | 3.53 | 3.78 | 4.05 | 4.11 | 4.45 | 4.59 | 4.94 | 5.21 | 5.62 | 5.44 |
| 1% Diclofenac Sodium+3% Menthol | 7.8 | 0.23 | 0.44 | 0.56 | 0.71 | 0.79 | 0.84 | 1.19 | 1.62 | 1.59 | 1.91 | 2.41 | 2.55 | 2.84 | 3.10 | 3.34 | 3.38 | 3.70 | 3.76 | 4.17 | 4.26 | 4.58 | 4.55 | 5.17 | 5.28 | 5.71 | 5.56 |
| 3% Menthol | 7.8 | 0.29 | 0.49 | 0.64 | 0.79 | 0.91 | 1.17 | 1.44 | 1.75 | 1.55 | 2.04 | 2.56 | 2.55 | 3.08 | 3.03 | 3.48 | 3.35 | 3.72 | 3.68 | 3.95 | 3.90 | 4.37 | 4.21 | 4.87 | 4.87 | 5.28 | 5.41 |
| Placebo | 7.7 | 0.32 | 0.55 | 0.64 | 0.69 | 0.87 | 0.95 | 1.16 | 1.53 | 1.32 | 1.92 | 2.05 | 2.28 | 2.68 | 2.78 | 3.18 | 3.14 | 3.47 | 3.59 | 3.88 | 3.95 | 4.08 | 4.22 | 4.56 | 4.78 | 5.01 | 5.60 |
Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment. (NCT02100670)
Timeframe: Day 1 to Day 7
| Intervention | score on a scale (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 10 min. (n= 117, 111, 77, 74) | At 30 min. (n=117, 111, 77, 75) | At 1 hour (n=116, 112, 77, 75) | At 4 hour (n= 115, 110, 74, 71) | At 6 hour (n= 109, 105, 70, 69) | At 12 hour (n= 77, 89, 53, 58) | At 18 hour (n= 76, 78, 53, 57) | At 24 hour (n= 111, 105, 72, 72) | At 36 hour (n= 116, 112, 77, 74) | At 48 hour (n= 116, 112, 77, 75) | At 60 hour (n=115, 111, 77, 75) | At 72 hour (n= 114, 109, 75, 74) | At 84 hour (n= 113, 106, 75, 75) | At 96 hour (n= 112, 106, 75, 74) | At 108 hour (n= 111, 105, 75, 74) | At 120 hour (n= 111, 107, 74, 72) | At 132 hour (n= 110, 107, 73, 74) | At 144 hour (n= 110, 107, 74, 73) | At 156 hour (n= 109, 106, 74, 74) | At 168 hour (n= 105, 103, 73, 73) | |
| 1% Diclofenac Sodium | 0.29 | 0.36 | 0.46 | 0.45 | 0.54 | 0.72 | 0.73 | 0.74 | 0.84 | 0.84 | 1.00 | 1.06 | 1.00 | 1.03 | 1.13 | 1.14 | 1.24 | 1.21 | 1.30 | 1.31 |
| 1% Diclofenac Sodium+3% Menthol | 0.33 | 0.44 | 0.48 | 0.47 | 0.50 | 0.60 | 0.71 | 0.79 | 0.84 | 0.90 | 1.07 | 0.93 | 1.07 | 1.09 | 1.18 | 1.11 | 1.34 | 1.21 | 1.41 | 1.41 |
| 3% Menthol | 0.32 | 0.49 | 0.57 | 0.51 | 0.63 | 0.74 | 0.83 | 0.90 | 0.88 | 0.99 | 1.16 | 1.16 | 1.25 | 1.01 | 1.28 | 1.24 | 1.34 | 1.30 | 1.47 | 1.34 |
| Placebo | 0.36 | 0.44 | 0.40 | 0.49 | 0.45 | 0.62 | 0.70 | 0.81 | 0.78 | 0.99 | 0.96 | 0.97 | 1.11 | 1.09 | 1.15 | 1.10 | 1.30 | 1.27 | 1.32 | 1.40 |
PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent) (NCT02100670)
Timeframe: up to Day 10
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Poor=0 | Fair=1 | Good=2 | Very Good=3 | Excellent=4 | |
| 1% Diclofenac Sodium | 13 | 20 | 46 | 26 | 6 |
| 1% Diclofenac Sodium+3% Menthol | 3 | 24 | 44 | 35 | 9 |
| 3% Menthol | 6 | 12 | 26 | 26 | 5 |
| Placebo | 9 | 14 | 27 | 21 | 4 |
"PID at rest was calculated as PI at a given time point't' (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).~PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PI at Baseline (n=117, 112, 77, 75) | PID at 10 min. (n=117, 112, 77, 75) | PID at 30 min. (n=117, 112, 77, 75) | PID at 1 hour (n=117, 112, 77, 75) | PID at 4 hour (n=117, 112, 77, 75) | PID at 6 hour (n= 117, 112, 77, 75) | PID at 12 hour (n= 117, 112, 77, 75) | PID at 18 hour (n= 117, 112, 77, 75) | PID at 24 hour (n= 117, 112, 77, 75) | PID at 36 hour (n= 117, 112, 77, 75) | PID at 48 hour (n=117, 112, 77, 75) | PID at 60 hour (n= 117, 112, 77, 75) | PID at 72 hour (n= 117, 112, 77, 75) | PID at 84 hour (n= 113, 107, 75, 75) | PID at 96 hour (n= 112, 107, 75, 74) | PID at 108 hour (n=112, 107, 75, 74) | PID at 120 hour (n= 111, 107, 74, 74) | PID at 132 hour (n= 110, 107, 74, 74) | PID at 144 hour (n= 110, 107, 74, 74) | PID at 156 hour (n= 109, 107, 74, 74) | PID at 168 hour (n= 105, 104, 73, 74) | PID at 180 hour (n= 105, 104, 73, 72) | PID at 192 hour (n= 101, 102, 71, 72) | PID at 204 hour (n= 101, 100, 71, 72) | PID at 216 hour (n= 95, 100, 69, 72) | PID at 228 hour (n= 95, 100, 69, 72) | PID at 240 hour (n= 32, 43, 22, 42) | |
| 1% Diclofenac Sodium | 7.4 | 0.43 | 0.45 | 0.62 | 0.53 | 0.62 | 0.86 | 1.14 | 1.39 | 1.32 | 1.53 | 1.83 | 1.91 | 2.19 | 2.17 | 2.43 | 2.48 | 2.78 | 2.77 | 3.11 | 3.15 | 3.38 | 3.30 | 3.61 | 3.87 | 4.02 | 4.23 |
| 1% Diclofenac Sodium+3% Menthol | 7.8 | 0.34 | 0.56 | 0.64 | 0.62 | 0.68 | 0.76 | 1.03 | 1.32 | 1.20 | 1.43 | 1.91 | 1.91 | 2.11 | 2.26 | 2.46 | 2.59 | 2.76 | 2.77 | 3.06 | 3.08 | 3.37 | 3.38 | 3.67 | 3.77 | 4.09 | 3.94 |
| 3% Menthol | 7.8 | 0.17 | 0.32 | 0.48 | 0.66 | 0.75 | 0.90 | 1.10 | 1.47 | 1.22 | 1.51 | 1.88 | 1.86 | 2.19 | 2.23 | 2.48 | 2.30 | 2.68 | 2.59 | 2.77 | 2.75 | 2.95 | 2.90 | 3.37 | 3.22 | 3.64 | 3.36 |
| Placebo | 7.7 | 0.25 | 0.44 | 0.41 | 0.43 | 0.53 | 0.68 | 0.85 | 1.13 | 1.09 | 1.45 | 1.64 | 1.76 | 2.03 | 2.00 | 2.27 | 2.09 | 2.49 | 2.49 | 2.65 | 2.64 | 2.88 | 3.00 | 3.21 | 3.26 | 3.53 | 3.67 |
Skin temperature was measured by thermal imaging. (NCT02100670)
Timeframe: At 10, 30, 60 minutes, 4 and 6 hours
| Intervention | degree celsius (°C) (Mean) | ||||
|---|---|---|---|---|---|
| At 10 min. | At 30 min. | At 60 min. | At 240 min. | At 360 min. | |
| 1% Diclofenac Sodium | 29.31 | 29.81 | 30.74 | 31.26 | 31.53 |
| 1% Diclofenac Sodium+3% Menthol | 27.69 | 28.26 | 28.64 | 30.52 | 31.02 |
| 3% Menthol | 29.92 | 30.50 | 30.22 | 31.15 | 31.27 |
| Placebo | 30.93 | 31.47 | 31.78 | 31.57 | 32.07 |
SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief. (NCT02100670)
Timeframe: Baseline to Day 7
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| At 0-6 hours | At 0-12 hours | At 0-1 days | At 1 to 3 days | At 0 to 7 days | |
| 1% Diclofenac Sodium | 3.19 | 9.13 | 26.54 | 100.07 | 452.44 |
| 1% Diclofenac Sodium+3% Menthol | 4.16 | 9.19 | 26.01 | 101.54 | 451.12 |
| 3% Menthol | 4.72 | 11.74 | 30.91 | 104.26 | 464.96 |
| Placebo | 4.37 | 10.05 | 26.21 | 90.88 | 438.45 |
TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672. (NCT02100670)
Timeframe: Baseline to 168 hours
| Intervention | PRS Score (0 - 4 scale) (Mean) | |||||
|---|---|---|---|---|---|---|
| 0-6 hours | 0-12 hours | 0- 24 hours | 0-72 hours | 24-72 hours | 0-168 hours | |
| 1% Diclofenac Sodium | 2.64 | 6.81 | 16.14 | 61.24 | 45.11 | 170.73 |
| 1% Diclofenac Sodium+3% Menthol | 2.81 | 6.86 | 16.04 | 60.14 | 44.10 | 172.97 |
| 3% Menthol | 3.27 | 8.02 | 18.85 | 66.69 | 47.84 | 184.17 |
| Placebo | 2.75 | 6.35 | 15.71 | 58.75 | 43.04 | 174.00 |
3 reviews available for menthol and Ache
| Article | Year |
|---|---|
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Asthma; Humans; Ion Channel Gating; Neurons; Pain; Pe | 2010 |
Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.
Topics: Analgesics; Camphor; Cough; Humans; Menthol; Pain; Transient Receptor Potential Channels; TRPA1 Cati | 2023 |
The role and mechanism of action of menthol in topical analgesic products.
Topics: Administration, Cutaneous; Analgesics; Humans; Menthol; Pain; TRPM Cation Channels | 2018 |
13 trials available for menthol and Ache
| Article | Year |
|---|---|
Menthol-Based Topical Analgesic Induces Similar Upper and Lower Body Pain Pressure Threshold Values: A Randomized Trial.
Topics: Achilles Tendon; Analgesics; Female; Humans; Male; Menthol; Pain; Pain Threshold | 2022 |
Topical application of isolated menthol and combined menthol-capsaicin creams: Exercise tolerance, thermal perception, pain, attentional focus and thermoregulation in the heat.
Topics: Adult; Body Temperature Regulation; Capsaicin; Cross-Over Studies; Exercise Tolerance; Female; Hot T | 2023 |
Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Ankle; Ankle Injuries; Anti-Inflammatory Agents, Non-S | 2017 |
Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries.
Topics: Administration, Topical; Adolescent; Adult; Aged; Diclofenac; Female; Gels; Humans; Ibuprofen; Male; | 2019 |
Psychophysical and Vasomotor Responses of the Oral Tissues: A Nicotine Dose-Response and Menthol Interaction Study.
Topics: Adult; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 2016 |
Olfactory and trigeminal interaction of menthol and nicotine in humans.
Topics: Adult; Analysis of Variance; Cross-Sectional Studies; Dose-Response Relationship, Drug; Double-Blind | 2012 |
Topical menthol--a human model for cold pain by activation and sensitization of C nociceptors.
Topics: Administration, Topical; Adult; Aged; Antipruritics; Cold Temperature; Double-Blind Method; Female; | 2004 |
A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis.
Topics: Activities of Daily Living; Administration, Topical; Aged; Arthritis; Drug Combinations; Elbow; Fatt | 2005 |
TRPA1 and TRPM8 activation in humans: effects of cinnamaldehyde and menthol.
Topics: Acrolein; Adult; Axons; Cross-Over Studies; Double-Blind Method; Female; Humans; Hyperalgesia; Ion C | 2005 |
Menthol facilitates the skin analgesic effect of tetracaine gel.
Topics: Adult; Anesthetics, Local; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Comb | 2005 |
Role of TRPM8 and TRPA1 for cold allodynia in patients with cold injury.
Topics: Acrolein; Adult; Afferent Pathways; Calcium Channels; Cold Temperature; Cross-Over Studies; Double-B | 2008 |
The effects of analgesics on pain-related somatosensory evoked potentials.
Topics: Analgesics; Carbon Dioxide; Dental Pulp; Dipyrone; Electric Stimulation; Evoked Potentials; Humans; | 1986 |
Effects of a counterirritant on perceived pain and hand movement in patients with arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Audiometry; Female; Finger Joint; Hand; Humans; Irritants; Male; | 1973 |
27 other studies available for menthol and Ache
| Article | Year |
|---|---|
Pain and Menthol Use Are Related to Greater Nicotine Dependence Among Black Adults Who Smoke Cigarettes at Wave 5 (2018-2019) of the Population Assessment of Tobacco and Health (PATH) Study.
Topics: Adult; Cigarette Smoking; Humans; Menthol; Nicotiana; Pain; Tobacco Products; Tobacco Use Disorder | 2023 |
Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine.
Topics: Animals; Calcium; Cricetinae; Cricetulus; Fura-2; Ganglia, Spinal; HEK293 Cells; Humans; Menthol; Mi | 2023 |
Human Osteoarthritic Chondrocytes Express Nineteen Different TRP-Genes-TRPA1 and TRPM8 as Potential Drug Targets.
Topics: Chondrocytes; Dexamethasone; Humans; Membrane Proteins; Menthol; Pain; Protein Serine-Threonine Kina | 2023 |
Nociceptive-like behavior and analgesia in silver catfish (Rhamdia quelen).
Topics: Acetic Acid; Analgesia; Analgesics, Opioid; Animals; Catfishes; Disease Models, Animal; Injections; | 2019 |
Unveiling new mechanisms for cold sensitization.
Topics: Ankyrins; Humans; Menthol; Neurogenic Inflammation; Nociception; Pain; Receptors, Nerve Growth Facto | 2021 |
Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy.
Topics: Acrylamides; Animals; Animals, Newborn; Antipruritics; Bridged Bicyclo Compounds, Heterocyclic; Derm | 2018 |
Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Drug Compoun | 2018 |
Menthol cigarette use and pain reporting among African American adults seeking treatment for smoking cessation.
Topics: Adult; Black or African American; Cigarette Smoking; Female; Humans; Male; Menthol; Middle Aged; Mot | 2019 |
A woman with an itchy hyperpigmentation on her back.
Topics: Aged; Back; Female; Histamine Antagonists; Humans; Hyperpigmentation; Menthol; Pain; Pruritus; Skin; | 2019 |
The infusion of menthol into the esophagus evokes cold sensations in healthy subjects but induces heartburn in patients with gastroesophageal reflux disease (GERD).
Topics: Adult; Afferent Pathways; Aged; Esophagus; Female; Gastroesophageal Reflux; Healthy Volunteers; Hear | 2019 |
AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia.
Topics: Action Potentials; Animals; Behavior, Animal; Blood Pressure; Brain; Calcium; CHO Cells; Cold Temper | 2015 |
Cold and L-menthol-induced sensitization in healthy volunteers--a cold hypersensitivity analogue to the heat/capsaicin model.
Topics: Administration, Topical; Adult; Capsaicin; Cold Temperature; Female; Hand; Hot Temperature; Humans; | 2015 |
Residual spinothalamic tract pathways predict development of central pain after spinal cord injury.
Topics: Adult; Capsaicin; Cold Temperature; Female; Histamine; Hot Temperature; Humans; Male; Menthol; Middl | 2008 |
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Borte | 2008 |
The contribution of TRPM8 and TRPA1 channels to cold allodynia and neuropathic pain.
Topics: Animals; Ankyrins; Calcium; Calcium Channels; Cold Temperature; Ganglia, Spinal; Male; Menthol; Mice | 2009 |
NPPB structure-specifically activates TRPA1 channels.
Topics: Calcium Channels; Cell Line; Humans; Isothiocyanates; Kidney; Menthol; Mutagenesis; Nerve Tissue Pro | 2010 |
Topical application of L-menthol induces heat analgesia, mechanical allodynia, and a biphasic effect on cold sensitivity in rats.
Topics: Administration, Topical; Aging; Animals; Antipruritics; Cold Temperature; Dose-Response Relationship | 2010 |
Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model.
Topics: Administration, Topical; Adult; Antipruritics; Dose-Response Relationship, Drug; Hand; Humans; Hyper | 2011 |
A novel human volunteer pain model using contact heat evoked potentials (CHEP) following topical skin application of transient receptor potential agonists capsaicin, menthol and cinnamaldehyde.
Topics: Acrolein; Adult; Capsaicin; Electroencephalography; Evoked Potentials; Female; Hot Temperature; Huma | 2011 |
Menthol pain relief through cumulative inactivation of voltage-gated sodium channels.
Topics: Analgesics; Animals; Cell Line, Tumor; Hybrid Cells; Male; Menthol; Mice; Mice, Inbred C57BL; NAV1.8 | 2012 |
Thermal grill-evoked sensations of heat correlate with cold pain threshold and are enhanced by menthol and cinnamaldehyde.
Topics: Acrolein; Adult; Cold Temperature; Female; Hot Temperature; Humans; Male; Menthol; Nociceptors; Pain | 2013 |
Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key.
Topics: Administration, Topical; Animals; Antipruritics; Capsaicin; Humans; Menthol; Pain; Pruritus Ani; Rec | 2003 |
TRACTION DEVICE EASES PAIN OF TRAVEL.
Topics: Humans; Menthol; Pain; Traction; Travel | 1964 |
Desensitization of cold- and menthol-sensitive rat dorsal root ganglion neurones by inflammatory mediators.
Topics: Analgesia; Animals; Ankyrins; Antipruritics; Calcium Channels; Cells, Cultured; Cold Temperature; Cy | 2007 |
Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin.
Topics: Administration, Topical; Adult; Biophysical Phenomena; Biophysics; Female; Histamine; Hot Temperatur | 1996 |
Sensory experiences in humans and single-unit activity in cats evoked by polymodal stimulation of the cornea.
Topics: Acids; Adult; Animals; Antipruritics; Carbon Dioxide; Cats; Cold Temperature; Cornea; Female; Hot Te | 2001 |
[Therapeutic experiences with Dolo-Menthoneuringel].
Topics: Back Pain; Drug Combinations; Evaluation Studies as Topic; Gels; Heparin; Humans; Menthol; Neuralgia | 1973 |